BIOMAT Database Logo BIOMAT Database Logo

De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors. 2018

Matthieu Peyre, and Guillaume Gauchotte, and Marine Giry, and Sébastien Froehlich, and Johan Pallud, and Thomas Graillon, and Franck Bielle, and Dominique Cazals-Hatem, and Pascale Varlet, and Dominique Figarella-Branger, and Hugues Loiseau, and Michel Kalamarides
Department of Neurosurgery, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France.

Following recent studies underlining the differences between de novo and secondary anaplastic meningiomas and the prognostic value of telomerase reverse transcriptase (TERT) promoter mutation, we decided to conduct a multicenter retrospective study to address these questions and determine specific prognostic factors in each of these 2 anaplastic meningioma subgroups. Among the 68 meningioma cases initially selected, only 57 were confirmed as anaplastic meningiomas after centralized pathological review. TERT promoter mutation analysis was performed in all cases. Median overall survival was 2.6 years and 5-year survival rate was 10%. This study confirmed the better prognosis of de novo anaplastic meningiomas (28 tumors) compared with secondary anaplastic meningiomas (29 tumors) (P = 0.02). In the "de novo" group, meningiomas diagnosed on histological anaplasia alone had a better prognosis than those in patients with a high number of mitoses with or without anaplasia (P = 0.01). In the "secondary" group, tumors demonstrate very heterogeneous clinical courses leading to malignant transformation, and time to first relapse as a low-grade tumor was a strong predictor of overall survival (P = 0.0007). TERT promoter mutation in anaplastic meningiomas was rare (14%) and did not influence overall survival but was associated with a shorter recurrence-free survival in the secondary anaplastic meningioma subgroup (P = 0.02). The absence of TERT promoter methylation, although rare (3/33 cases), may be associated with prolonged overall survival (P = 0.02). This study highlights the different prognoses of de novo and secondary anaplastic meningiomas with specific prognostic factors in each subgroup. The analysis of TERT mutation and methylation could provide additional prognostic insights.

UI MeSH Term Description Entries
D008297 Male Males
D008577 Meningeal Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord. Intracranial Meningeal Neoplasms,Spinal Meningeal Neoplasms,Benign Meningeal Neoplasms,Leptomeningeal Neoplasms,Malignant Meningeal Neoplasms,Meningeal Cancer,Meningeal Neoplasms, Benign,Meningeal Neoplasms, Intracranial,Meningeal Neoplasms, Malignant,Meningeal Tumors,Neoplasms, Leptomeningeal,Neoplasms, Meningeal,Benign Meningeal Neoplasm,Cancer, Meningeal,Cancers, Meningeal,Intracranial Meningeal Neoplasm,Leptomeningeal Neoplasm,Malignant Meningeal Neoplasm,Meningeal Cancers,Meningeal Neoplasm,Meningeal Neoplasm, Benign,Meningeal Neoplasm, Intracranial,Meningeal Neoplasm, Malignant,Meningeal Neoplasm, Spinal,Meningeal Neoplasms, Spinal,Meningeal Tumor,Neoplasm, Benign Meningeal,Neoplasm, Intracranial Meningeal,Neoplasm, Leptomeningeal,Neoplasm, Malignant Meningeal,Neoplasm, Meningeal,Neoplasm, Spinal Meningeal,Neoplasms, Benign Meningeal,Neoplasms, Intracranial Meningeal,Neoplasms, Malignant Meningeal,Neoplasms, Spinal Meningeal,Spinal Meningeal Neoplasm,Tumor, Meningeal,Tumors, Meningeal
D008579 Meningioma A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7) Benign Meningioma,Malignant Meningioma,Meningiomas, Multiple,Meningiomatosis,Angioblastic Meningioma,Angiomatous Meningioma,Cerebral Convexity Meningioma,Clear Cell Meningioma,Fibrous Meningioma,Hemangioblastic Meningioma,Hemangiopericytic Meningioma,Intracranial Meningioma,Intraorbital Meningioma,Intraventricular Meningioma,Meningotheliomatous Meningioma,Microcystic Meningioma,Olfactory Groove Meningioma,Papillary Meningioma,Parasagittal Meningioma,Posterior Fossa Meningioma,Psammomatous Meningioma,Secretory Meningioma,Sphenoid Wing Meningioma,Spinal Meningioma,Transitional Meningioma,Xanthomatous Meningioma,Angioblastic Meningiomas,Angiomatous Meningiomas,Benign Meningiomas,Cerebral Convexity Meningiomas,Clear Cell Meningiomas,Convexity Meningioma, Cerebral,Convexity Meningiomas, Cerebral,Fibrous Meningiomas,Groove Meningiomas, Olfactory,Hemangioblastic Meningiomas,Hemangiopericytic Meningiomas,Intracranial Meningiomas,Intraorbital Meningiomas,Intraventricular Meningiomas,Malignant Meningiomas,Meningioma, Angioblastic,Meningioma, Angiomatous,Meningioma, Benign,Meningioma, Cerebral Convexity,Meningioma, Clear Cell,Meningioma, Fibrous,Meningioma, Hemangioblastic,Meningioma, Hemangiopericytic,Meningioma, Intracranial,Meningioma, Intraorbital,Meningioma, Intraventricular,Meningioma, Malignant,Meningioma, Meningotheliomatous,Meningioma, Microcystic,Meningioma, Multiple,Meningioma, Olfactory Groove,Meningioma, Papillary,Meningioma, Parasagittal,Meningioma, Posterior Fossa,Meningioma, Psammomatous,Meningioma, Secretory,Meningioma, Sphenoid Wing,Meningioma, Spinal,Meningioma, Transitional,Meningioma, Xanthomatous,Meningiomas,Meningiomas, Angioblastic,Meningiomas, Angiomatous,Meningiomas, Benign,Meningiomas, Cerebral Convexity,Meningiomas, Clear Cell,Meningiomas, Fibrous,Meningiomas, Hemangioblastic,Meningiomas, Hemangiopericytic,Meningiomas, Intracranial,Meningiomas, Intraorbital,Meningiomas, Intraventricular,Meningiomas, Malignant,Meningiomas, Meningotheliomatous,Meningiomas, Microcystic,Meningiomas, Olfactory Groove,Meningiomas, Papillary,Meningiomas, Parasagittal,Meningiomas, Posterior Fossa,Meningiomas, Psammomatous,Meningiomas, Secretory,Meningiomas, Sphenoid Wing,Meningiomas, Spinal,Meningiomas, Transitional,Meningiomas, Xanthomatous,Meningiomatoses,Meningotheliomatous Meningiomas,Microcystic Meningiomas,Multiple Meningioma,Multiple Meningiomas,Olfactory Groove Meningiomas,Papillary Meningiomas,Parasagittal Meningiomas,Posterior Fossa Meningiomas,Psammomatous Meningiomas,Secretory Meningiomas,Sphenoid Wing Meningiomas,Spinal Meningiomas,Transitional Meningiomas,Wing Meningioma, Sphenoid,Wing Meningiomas, Sphenoid,Xanthomatous Meningiomas
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D005260 Female Females

Related Publications

Matthieu Peyre, and Guillaume Gauchotte, and Marine Giry, and Sébastien Froehlich, and Johan Pallud, and Thomas Graillon, and Franck Bielle, and Dominique Cazals-Hatem, and Pascale Varlet, and Dominique Figarella-Branger, and Hugues Loiseau, and Michel Kalamarides
De novo and secondary anaplastic meningiomas: natural history, prognosis, and the TERT promoter.
July 2018, Neuro-oncology,
Matthieu Peyre, and Guillaume Gauchotte, and Marine Giry, and Sébastien Froehlich, and Johan Pallud, and Thomas Graillon, and Franck Bielle, and Dominique Cazals-Hatem, and Pascale Varlet, and Dominique Figarella-Branger, and Hugues Loiseau, and Michel Kalamarides
De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome.
September 2007, Neurosurgery,
Matthieu Peyre, and Guillaume Gauchotte, and Marine Giry, and Sébastien Froehlich, and Johan Pallud, and Thomas Graillon, and Franck Bielle, and Dominique Cazals-Hatem, and Pascale Varlet, and Dominique Figarella-Branger, and Hugues Loiseau, and Michel Kalamarides
Survival rates, prognostic factors and treatment of anaplastic meningiomas.
May 2015, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Matthieu Peyre, and Guillaume Gauchotte, and Marine Giry, and Sébastien Froehlich, and Johan Pallud, and Thomas Graillon, and Franck Bielle, and Dominique Cazals-Hatem, and Pascale Varlet, and Dominique Figarella-Branger, and Hugues Loiseau, and Michel Kalamarides
Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study.
June 2013, Journal of neurosurgical sciences,
Matthieu Peyre, and Guillaume Gauchotte, and Marine Giry, and Sébastien Froehlich, and Johan Pallud, and Thomas Graillon, and Franck Bielle, and Dominique Cazals-Hatem, and Pascale Varlet, and Dominique Figarella-Branger, and Hugues Loiseau, and Michel Kalamarides
Survival and Prognostic Predictors of Anaplastic Meningiomas.
November 2019, World neurosurgery,
Matthieu Peyre, and Guillaume Gauchotte, and Marine Giry, and Sébastien Froehlich, and Johan Pallud, and Thomas Graillon, and Franck Bielle, and Dominique Cazals-Hatem, and Pascale Varlet, and Dominique Figarella-Branger, and Hugues Loiseau, and Michel Kalamarides
Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
May 2008, Journal of neurology, neurosurgery, and psychiatry,
Matthieu Peyre, and Guillaume Gauchotte, and Marine Giry, and Sébastien Froehlich, and Johan Pallud, and Thomas Graillon, and Franck Bielle, and Dominique Cazals-Hatem, and Pascale Varlet, and Dominique Figarella-Branger, and Hugues Loiseau, and Michel Kalamarides
Timing of H3K27me3 loss in secondary anaplastic meningiomas.
July 2022, Brain tumor pathology,
Matthieu Peyre, and Guillaume Gauchotte, and Marine Giry, and Sébastien Froehlich, and Johan Pallud, and Thomas Graillon, and Franck Bielle, and Dominique Cazals-Hatem, and Pascale Varlet, and Dominique Figarella-Branger, and Hugues Loiseau, and Michel Kalamarides
Paths of Evolution of Progressive Anaplastic Meningiomas: A Clinical and Molecular Pathology Study.
January 2023, Journal of personalized medicine,
Matthieu Peyre, and Guillaume Gauchotte, and Marine Giry, and Sébastien Froehlich, and Johan Pallud, and Thomas Graillon, and Franck Bielle, and Dominique Cazals-Hatem, and Pascale Varlet, and Dominique Figarella-Branger, and Hugues Loiseau, and Michel Kalamarides
Molecular and genetic profiles of radiographically defined de novo meningiomas.
May 2012, Journal of neuro-oncology,
Matthieu Peyre, and Guillaume Gauchotte, and Marine Giry, and Sébastien Froehlich, and Johan Pallud, and Thomas Graillon, and Franck Bielle, and Dominique Cazals-Hatem, and Pascale Varlet, and Dominique Figarella-Branger, and Hugues Loiseau, and Michel Kalamarides
Anaplastic Meningioma: Clinical Characteristics, Prognostic Factors and Survival Outcome.
October 2022, Brain tumor research and treatment,
Copied contents to your clipboard!